Apoptosis-related BCL2-family members: Key players in chemotherapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 3, 2014, Pages 353-374

  Kontos, Christos K ^a   Christodoulou, Maria Ioanna ^a   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Anticancer agents; Antineoplastic agents; Chemotherapeutic drugs; Molecular tumor markers; Monoclonal antibody therapy; Targeted therapy

Indexed keywords

AZACITIDINE; BAFETINIB; BENDAMUSTINE; BEVACIZUMAB; BLEOMYCIN; BORTEZOMIB; BOSUTINIB; BUSULFAN; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CETUXIMAB; CHIR 265; CHLORMETHINE; CISPLATIN; CLADRIBINE; CLOFARABINE; CRIZOTINIB; DACTINOMYCIN; DASATINIB; DAUNORUBICIN; DINACICLIB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE B; ERLOTINIB; ESTRAMUSTINE; ETOPOFOS; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE PHOSPHATE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IDARUBICIN; IMATINIB; IRINOTECAN; IXABEPILONE; LAPATINIB; LESTAURTINIB; MELPHALAN; METHOTREXATE; MITOMYCIN; NAVELBINE; NILOTINIB; OBATOCLAX; OXALIPLATIN; PACLITAXEL; PARAPLATIN AQ; PAZOPANIB; PEMECAD; PEMETREXED; PENTOSTATIN; PLATIN; PROTEIN BCL 2; RITUXIMAB; SELUMETINIB; SORAFENIB; STREPTOZOCIN; TEGAFUR; TOPOTECAN; TRASTUZUMAB; TREAKISYM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN; VANDETANIB; VEMURAFENIB; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; BREAST CANCER; BREAST METASTASIS; CELL FATE; CELL PROLIFERATION; CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DOWN REGULATION; EWING SARCOMA; GENE EXPRESSION; GERM CELL TUMOR; GLIOBLASTOMA; HAIRY CELL LEUKEMIA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HODGKIN DISEASE; HUMAN; KAPOSI SARCOMA; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONLYMPHATIC LEUKEMIA; OVARY CANCER; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHORYLATION; PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SARCOMA; SIGNAL TRANSDUCTION; STOMACH CANCER; TESTIS CANCER; UPREGULATION; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84894080217     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113139990091     Document Type: Review

References (324)

1. Kerr, J.F.; Wyllie, A.H.; Currie, A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer, 1972, 26(4), 239-257.
2. Sasi, N.; Hwang, M.; Jaboin, J.; Csiki, I.; Lu, B. Regulated cell death pathways: new twists in modulation of BCL2 family function. Mol. Cancer Ther., 2009, 8(6), 1421-1429.
3. Saikumar, P.; Dong, Z.; Mikhailov, V.; Denton, M.; Weinberg, J.M.; Venkatachalam, M.A. Apoptosis: Definition, mechanisms, and relevance to disease. Am. J. Med., 1999, 107(5), 489-506.
4. Reed, J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol., 1999, 17(9), 2941-2953.
5. Krajewski, S.; Krajewska, M.; Turner, B.C.; Pratt, C.; Howard, B.; Zapata, J.M.; Frenkel, V.; Robertson, S.; Ionov, Y.; Yamamoto, H.; Perucho, M.; Takayama, S.; Reed, J.C. Prognostic significance of apoptosis regulators in breast cancer. Endocr. Relat. Cancer, 1999, 6(1), 29-40.
6. Hueber, A.O.; Evan, G.I. Traps to catch unwary oncogenes. Trends Genet., 1998, 14(9), 364-367.
7. Harris, A.L. Hypoxia--a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2002, 2(1), 38-47.
8. Reed, J.C. Mechanisms of apoptosis. Am. J. Pathol., 2000, 157(5), 1415-1430.
9. Petros, A.M.; Olejniczak, E.T.; Fesik, S.W. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta, 2004, 1644(2-3), 83-94.
10. Adams, J.M.; Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science, 1998, 281(5381), 1322-1326.
11. Yip, K.W.; Reed, J.C. Bcl-2 family proteins and cancer. Oncogene, 2008, 27(50), 6398-6406.
12. Thomadaki, H.; Scorilas, A. BCL2 family of apoptosis-related genes: Functions and clinical implications in cancer. Crit. Rev. Clin. Lab Sci., 2006, 43(1), 1-67.
13. Malhotra, V.; Perry, M.C. Classical chemotherapy: mechanisms, toxicities and the therapeutic window. Cancer Biol. Ther., 2003, 2(4 Suppl 1), S2-4.
14. Marino, D.; Leone, F.; Cavalloni, G.; Cagnazzo, C.; Aglietta, M. Biliary tract carcinomas: From chemotherapy to targeted therapy. Crit. Rev. Oncol. Hematol., 2013, 85(2), 136-148.
15. Campos, S.M.; Dizon, D.S. Antimitotic inhibitors. Hematol. Oncol. Clin. North Am., 2012, 26(3), 607-628.
16. Duflos, A.; Kruczynski, A.; Barret, J.M. Novel aspects of natural and modified vinca alkaloids. Curr. Med. Chem. Anti-Cancer Agents, 2002, 2(1), 55-70.
17. Hagiwara, H.; Sunada, Y. Mechanism of taxane neurotoxicity. Breast Cancer (Tokyo, Japan), 2004, 11(1), 82-85.
18. Ferrandina, G.; Mariani, M.; Andreoli, M.; Shahabi, S.; Scambia, G.; Ferlini, C. Novel drugs targeting microtubules: the role of epothilones. Curr. Pharm. Des., 2012, 18(19), 2793-2803.
19. Verma, P.; Mathur, A.K.; Srivastava, A.; Mathur, A. Emerging trends in research on spatial and temporal organization of terpenoid indole alkaloid pathway in Catharanthus roseus: a literature update. Protoplasma, 2012, 249(2), 255-268.
20. Zhu, B.K.; Wang, P.; Zhang, X.D.; Jiang, C.C.; Chen, L.H.; Avery-Kiejda, K.A.; Watts, R.; Hersey, P. Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells. Anticancer Drugs, 2008, 19(2), 189-200.
21. Shankar, S.; Chen, X.; Srivastava, R.K. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate, 2005, 62(2), 165-186.
22. Thomadaki, H.; Floros, K.V.; Scorilas, A. Molecular response of HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, including the new member BCL2L12. Ann. N Y Acad. Sci., 2009, 1171, 276-283.
23. Zhan, Z.; Li, Q.; Wu, P.; Ye, Y.; Tseng, H.Y.; Zhang, L.; Zhang, X.D. Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1. Autophagy, 2012, 8(1), 109-121.
24. Shinwari, Z.; Manogaran, P.S.; Alrokayan, S.A.; Al-Hussein, K.A.; Aboussekhra, A. Vincristine and lomustine induce apoptosis and p21(WAF1) up-regulation in medulloblastoma and normal human epithelial and fibroblast cells. J. Neurooncol., 2008, 87(2), 123-132.
25. Leveque, D.; Jehl, F. Clinical pharmacokinetics of vinorelbine. Clin. Pharmacokinet., 1996, 31(3), 184-197.
26. Galano, G.; Caputo, M.; Tecce, M.F.; Capasso, A. Efficacy and tolerability of vinorelbine in the cancer therapy. Curr. Drug Saf., 2011, 6(3), 185-193.
27. Chiu, W.H.; Luo, S.J.; Chen, C.L.; Cheng, J.H.; Hsieh, C.Y.; Wang, C.Y.; Huang, W.C.; Su, W.C.; Lin, C.F. Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells. Biochem. Pharmacol., 2012, 83(9), 1159-1171.
28. Bourgarel-Rey, V.; Savry, A.; Hua, G.; Carre, M.; Bressin, C.; Chacon, C.; Imbert, J.; Braguer, D.; Barra, Y. Transcriptional down-regulation of Bcl-2 by vinorelbine: identification of a novel binding site of p53 on Bcl-2 promoter. Biochem. Pharmacol., 2009, 78(9), 1148-1156.
29. Forest, V.; Hadjeres, R.; Bertrand, R.; Jean-Francois, R. Optimisation and molecular signalling of apoptosis in sequential cryotherapy and chemotherapy combination in human A549 lung cancer xenografts in SCID mice. Br. J. Cancer, 2009, 100(12), 1896-1902.
30. Gameiro, S.R.; Caballero, J.A.; Hodge, J.W. Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing. Cancer Biother. Radiopharm., 2012, 27(1), 23-35.
31. Roncuzzi, L.; Marti, G.; Baiocchi, D.; Del Coco, R.; Cocchi, S.; Gasperi-Campani, A. Effect of vinorelbine on cell growth and apoptosis induction in human osteosarcoma in vitro. Oncol. Rep., 2006, 15(1), 73-77.
32. Wani, M.C.; Taylor, H.L.; Wall, M.E.; Coggon, P.; McPhail, A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 1971, 93(9), 2325-2327.
33. Blagosklonny, M.V.; Fojo, T. Molecular effects of paclitaxel: myths and reality (a critical review). Int. J. Cancer, 1999, 83(2), 151-156.
34. Scatena, C.D.; Stewart, Z.A.; Mays, D.; Tang, L.J.; Keefer, C.J.; Leach, S.D.; Pietenpol, J.A. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J. Biol. Chem., 1998, 273(46), 30777-30784.
35. Ahn, H.J.; Kim, Y.S.; Kim, J.U.; Han, S.M.; Shin, J.W.; Yang, H.O. Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells. J. Cell Biochem., 2004, 91(5), 1043-1052.
36. Makhija, S.; Taylor, D.D.; Gibb, R.K.; Gercel-Taylor, C. Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids. Int. J. Oncol., 1999, 14(3), 515-521.
37. Yuan, S.Y.; Hsu, S.L.; Tsai, K.J.; Yang, C.R. Involvement of mitochondrial pathway in taxol-induced apoptosis of human T24 bladder cancer cells. Urol. Res., 2002, 30(5), 282-288.
38. Srivastava, R.K.; Mi, Q.S.; Hardwick, J.M.; Longo, D.L. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc. Natl. Acad. Sci. USA, 1999, 96(7), 3775-3780.
39. Haldar, S.; Chintapalli, J.; Croce, C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 1996, 56(6), 1253-1255.
40. Sunters, A.; De Mattos, F.S.; Stahl, M.; Brosens, J.J.; Zoumpoulidou, G.; Saunders, C.A.; Coffer, P.J.; Medema, R.H.; Coombes, R.C.; Lam, E.W. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J. Biol. Chem., 2003, 278(50), 49795-49805.
41. Kutuk, O.; Letai, A. Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. Cell Death Differ., 2010, 17(10), 1624-1635.
42. Maraz, A.; Furak, J.; Palfoldi, R.; Eller, J.; Szanto, E.; Kahan, Z.; Thurzo, L.; Molnar, J.; Tiszlavicz, L.; Hideghety, K. Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation. Anticancer Res., 2011, 31(4), 1431-1436.
43. Zhang, R.; Banik, N.L.; Ray, S.K. Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to taxol for apoptosis. Brain Res., 2008, 1239, 216-225.
44. Pushkarev, V.M.; Starenki, D.V.; Saenko, V.A.; Namba, H.; Kurebayashi, J.; Tronko, M.D.; Yamashita, S. Molecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cells. Endocrinology, 2004, 145(7), 3143-3152.
45. Zhou, H.B.; Zhu, J.R. Paclitaxel induces apoptosis in human gastric carcinoma cells. World J. Gastroenterol., 2003, 9(3), 442-445.
46. Gururajanna, B.; Al-Katib, A.A.; Li, Y.W.; Aranha, O.; Vaitkevicius, V.K.; Sarkar, F.H. Molecular effects of taxol and caffeine on pancreatic cancer cells. Int. J. Mol. Med., 1999, 4(5), 501-507.
47. Taguchi, T.; Kato, Y.; Baba, Y.; Nishimura, G.; Tanigaki, Y.; Horiuchi, C.; Mochimatsu, I.; Tsukuda, M. Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas. Oncol. Rep., 2004, 11(2), 421-426.
48. Nonaka, M.; Ikeda, H.; Fujisawa, A.; Uehara, M.; Inokuchi, T. Induction of apoptosis by paclitaxel in human oral carcinoma cells. Int. J. Oral Maxillofac. Surg., 2006, 35(7), 649-652.
49. Giannakakou, P.; Robey, R.; Fojo, T.; Blagosklonny, M.V. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene, 2001, 20(29), 3806-3813.
50. Bandyopadhyay, S.; Sengupta, T.K.; Fernandes, D.J.; Spicer, E.K. Taxol- and okadaic acid-induced destabilization of bcl-2 mRNA is associated with decreased binding of proteins to a bcl-2 instability element. Biochem. Pharmacol., 2003, 66(7), 1151-1162.
51. Thomadaki, H.; Scorilas, A. Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol. Biol. Chem., 2008, 389(11), 1427-1434.
52. Thomadaki, H.; Scorilas, A. Molecular profile of the BCL2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs. Connect. Tissue Res., 2008, 49(3), 261-264.
53. Thomadaki, H.; Talieri, M.; Scorilas, A. Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biol. Chem., 2006, 387(8), 1081-1086.
54. Kurokawa, H.; Nishio, K.; Fukumoto, H.; Tomonari, A.; Suzuki, T.; Saijo, N. Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. Oncol. Rep., 1999, 6(1), 33-37.
55. Mandlekar, S.; Yu, R.; Tan, T.H.; Kong, A.N. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res., 2000, 60(21), 5995-6000.
56. Korbakis, D.; Scorilas, A. Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. Tumour Biol., 2012, 33(3), 865-875.
57. Jiang, S.; Zu, Y.; Fu, Y.; Zhang, Y.; Efferth, T. Activation of the mitochondria-driven pathway of apoptosis in human PC-3 prostate cancer cells by a novel hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel. Int. J. Oncol., 2008, 33(1), 103-111.
58. Clarke, S.J.; Rivory, L.P. Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet., 1999, 36(2), 99-114.
59. Berchem, G.J.; Bosseler, M.; Mine, N.; Avalosse, B. Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. Anticancer Res., 1999, 19(1A), 535-540.
60. Escobar, P.F.; Rose, P.G. Docetaxel in ovarian cancer. Exp. Opin. Pharmacother., 2005, 6(15), 2719-2726.
61. Pienta, K.J. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin. Oncol., 2001, 28(4 Suppl 15), 3-7.
62. Mhaidat, N.M.; Wang, Y.; Kiejda, K.A.; Zhang, X.D.; Hersey, P. Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Mol. Cancer Ther., 2007, 6(2), 752-761.
63. Mhaidat, N.M.; Zhang, X.D.; Jiang, C.C.; Hersey, P. Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin. Cancer Res., 2007, 13(4), 1308-1314.
64. Takemura, K.; Noguchi, M.; Ogi, K.; Tokino, T.; Kubota, H.; Miyazaki, A.; Kohama, G.; Hiratsuka, H. Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy. J. Oral Pathol. Med., 2005, 34(2), 93-99.
65. Yoo, G.H.; Lin, H.S.; Iskander, A.J.; Piechocki, M.P.; Oliver, J.; Kewson, D.; Lonardo, F.; Tainsky, M.A.; Kim, H.R.; Kim, H.; Ensley, J.F. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study. Laryngoscope, 2005, 115(11), 1938-1946.
66. Freitas, M.; Alves, V.; Sarmento-Ribeiro, A.B.; Mota-Pinto, A. Combined effect of sodium selenite and docetaxel on PC3 metastatic prostate cancer cell line. Biochem. Biophys. Res. Commun., 2011, 408(4), 713-719.
67. Kim, S.M.; Lee, S.Y.; Cho, J.S.; Son, S.M.; Choi, S.S.; Yun, Y.P.; Yoo, H.S.; Do Yoon, Y.; Oh, K.W.; Han, S.B.; Hong, J.T. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB. Eur. J. Pharmacol., 2010, 631(1-3), 1-9.
68. Muramaki, M.; Miyake, H.; Hara, I.; Kamidono, S. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model. Int. J. Oncol., 2005, 26(3), 623-628.
69. Kim, S.M.; Lee, S.Y.; Yuk, D.Y.; Moon, D.C.; Choi, S.S.; Kim, Y.; Han, S.B.; Oh, K.W.; Hong, J.T. Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Arch. Pharm. Res., 2009, 32(5), 755-765.
70. Karabulut, B.; Erten, C.; Gul, M.K.; Cengiz, E.; Karaca, B.; Kucukzeybek, Y.; Gorumlu, G.; Atmaca, H.; Uzunoglu, S.; Sanli, U.A.; Baran, Y.; Uslu, R. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol. Int., 2009, 33(2), 239-246.
71. Liu, T.; Zhang, M.; Zhang, H.; Sun, C.; Yang, X.; Deng, Y.; Ji, W. Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur. J. Pharmacol., 2008, 587(1-3), 78-84.
72. Fauzee, N.J.; Wang, Y.L.; Dong, Z.; Li, Q.G.; Wang, T.; Mandarry, M.T.; Xu, L.; Pan, J. Novel hydrophilic docetaxel (CQMU-0519) analogue inhibits proliferation and induces apoptosis in human A549 lung, SKVO3 ovarian and MCF7 breast carcinoma cell lines. Cell Prolif., 2012, 45(4), 352-364.
73. Yamaguchi, H.; Chen, J.; Bhalla, K.; Wang, H.G. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. J. Biol. Chem., 2004, 279(38), 39431-39437.
74. Griffin, D.; Wittmann, S.; Guo, F.; Nimmanapalli, R.; Bali, P.; Wang, H.G.; Bhalla, K. Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells. Gynecol. Oncol., 2003, 89(1), 37-47.
75. Khawaja, N.R.; Carre, M.; Kovacic, H.; Esteve, M.A.; Braguer, D. Patupilone-induced apoptosis is mediated by mitochondrial reactive oxygen species through Bim relocalization to mitochondria. Mol. Pharmacol., 2008, 74(4), 1072-1083.
76. Fu, D.; Calvo, J.A.; Samson, L.D. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat. Rev. Cancer, 2012, 12(2), 104-120.
77. Brulikova, L.; Hlavac, J.; Hradil, P. DNA interstrand cross-linking agents and their chemotherapeutic potential. Curr. Med. Chem., 2012, 19(3), 364-385.
78. Armand, J.P.; Ribrag, V.; Harrousseau, J.L.; Abrey, L. Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Therap. Clin. Risk Manag., 2007, 3(2), 213-224.
79. Devaraj, N.K.; Weissleder, R. Biomedical applications of tetrazine cycloadditions. ACC. Chem. Res., 2011, 44(9), 816-827.
80. Lee, C.R.; Faulds, D. Altretamine. A review of its pharma-codynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy. Drugs, 1995, 49(6), 932-953.
81. Kelemen, E.; Tura, S. Mitobronitol: an alkylating agent that does not induce extra leukemia cases if applied as pulse therapy for polycythemia vera. Ann. N Y Acad. Sci., 1985, 459, 335.
82. Orlandi, E.; Bernasconi, P.; Boni, M.; Calatroni, S.; Lazzarino, M. Cytogenetic response to pipobroman in Philadelphia-positive chronic myeloid leukemia with thrombocythemic onset. Ann. Hematol., 2005, 84(2), 127-128.
83. Boddie, A.W., Jr.; Constantinou, A.; Williams, C.; Reed, A. Nitrogen mustard up-regulates Bcl-2 and GSH and increases NTP and PCr in HT-29 colon cancer cells. Br. J. Cancer, 1998, 77(9), 1395-1404.
84. Sharaf el dein, O.; Gallerne, C.; Brenner, C.; Lemaire, C. Increased expression of VDAC1 sensitizes carcinoma cells to apoptosis induced by DNA cross-linking agents. Biochem. Pharmacol., 2012, 83(9), 1172-1182.
85. Yoshida, D.; Noha, M.; Watanabe, K.; Takahashi, H.; Sugisaki, Y.; Teramoto, A. Induction of apoptosis by estramustine phosphate mediated by phosphorylation of bcl-2. J. Neurooncol., 2001, 54(1), 23-29.
86. Haldar, S.; Basu, A.; Croce, C.M. Bcl2 is the guardian of microtubule integrity. Cancer Res., 1997, 57(2), 229-233.
87. Facon, T.; Mary, J.Y.; Hulin, C.; Benboubker, L.; Attal, M.; Pegourie, B.; Renaud, M.; Harousseau, J.L.; Guillerm, G.; Chaleteix, C.; Dib, M.; Voillat, L.; Maisonneuve, H.; Troncy, J.; Dorvaux, V.; Monconduit, M.; Martin, C.; Casassus, P.; Jaubert, J.; Jardel, H.; Doyen, C.; Kolb, B.; Anglaret, B.; Grosbois, B.; Yakoub-Agha, I.; Mathiot, C.; Avet-Loiseau, H. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet, 2007, 370(9594), 1209-1218.
88. Osher, D.J.; Kushner, Y.B.; Arseneau, J.; Foulkes, W.D. Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks? J. Clin. Pathol., 2011, 64(10), 924-926.
89. Papadia, F.; Basso, V.; Patuzzo, R.; Maurichi, A.; Di Florio, A.; Zardi, L.; Ventura, E.; Gonzalez-Iglesias, R.; Lovato, V.; Giovannoni, L.; Tasciotti, A.; Neri, D.; Santinami, M.; Menssen, H.D.; De Cian, F. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. J. Surg. Oncol., 2013, 107(27), 173-179.
90. Gomez-Bougie, P.; Oliver, L.; Le Gouill, S.; Bataille, R.; Amiot, M. Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex. Oncogene, 2005, 24(54), 8076-8079.
91. Gomez-Bougie, P.; Bataille, R.; Amiot, M. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur. J. Immunol., 2004, 34(11), 3156-3164.
92. Kath, R.; Blumenstengel, K.; Fricke, H.J.; Hoffken, K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J. Cancer Res. Clin. Oncol., 2001, 127(1), 48-54.
93. Kalil, N.; Cheson, B.D. Management of chronic lymphocytic leukaemia. Drugs Aging, 2000, 16(1), 9-27.
94. Schwanen, C.; Hecker, T.; Hubinger, G.; Wolfle, M.; Rittgen, W.; Bergmann, L.; Karakas, T. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia, 2002, 16(10), 2096-2105.
95. Thomas, A.; Pepper, C.; Hoy, T.; Bentley, P. Bcl-2 and bax expression and chlorambucil-induced apoptosis in the T-cells and leukaemic B-cells of untreated B-cell chronic lymphocytic leukaemia patients. Leuk. Res., 2000, 24(10), 813-821.
96. Shanafelt, T.D.; Lin, T.; Geyer, S.M.; Zent, C.S.; Leung, N.; Kabat, B.; Bowen, D.; Grever, M.R.; Byrd, J.C.; Kay, N.E. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer, 2007, 109(11), 2291-2298.
97. Young, S.D.; Whissell, M.; Noble, J.C.; Cano, P.O.; Lopez, P.G.; Germond, C.J. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin. Cancer Res., 2006, 12(10), 3092-3098.
98. Gibson, L.F.; Fortney, J.; Magro, G.; Ericson, S.G.; Lynch, J.P.; Landreth, K.S. Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy. Breast Cancer Res. Treat., 1999, 55(2), 107-117.
99. Becker, R.; Ritter, A.; Eichhorn, U.; Lips, J.; Bertram, B.; Wiessler, M.; Zdzienicka, M.Z.; Kaina, B. Induction of DNA breaks and apoptosis in crosslink-hypersensitive V79 cells by the cytostatic drug beta-D-glucosyl-ifosfamide mustard. Br. J. Cancer, 2002, 86(1), 130-135.
100. Lytle, R.A.; Jiang, Z.; Zheng, X.; Rich, K.M. BCNU down-regulates anti-apoptotic proteins bcl-xL and Bcl-2 in association with cell death in oligodendroglioma-derived cells. J. Neurooncol., 2004, 68(3), 233-241.
101. Onoue, S.; Hanato, J.; Yamada, S. Pituitary adenylate cyclase-activating polypeptide attenuates streptozotocin-induced apoptotic death of RIN-m5F cells through regulation of Bcl-2 family protein mRNA expression. FEBS J., 2008, 275(22), 5542-5551.
102. Kern, M.A.; Helmbach, H.; Artuc, M.; Karmann, D.; Jurgovsky, K.; Schadendorf, D. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. Anticancer Res., 1997, 17(6D), 4359-4370.
103. Hassan, Z.; Hassan, M.; Hellstrom-Lindberg, E. The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro. Leukemia, 2001, 15(8), 1240-1247.
104. Meinhardt, G.; Dayyani, F.; Jahrsdorfer, B.; Baumgart, J.; Emmerich, B.; Schmidmaier, R. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br. J. Haematol., 2003, 122(6), 892-899.
105. Einhorn, L.H. Treatment of testicular cancer: a new and improved model. J. Clin. Oncol., 1990, 8(11), 1777-1781.
106. Floros, K.V.; Thomadaki, H.; Lallas, G.; Katsaros, N.; Talieri, M.; Scorilas, A. Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. Ann. N Y Acad. Sci., 2003, 1010, 153-158.
107. Thomadaki, H.; Scorilas, A. Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann. N Y Acad. Sci., 2007, 1095, 35-44.
108. Wu, Y.; Sato, F.; Bhawal, U.K.; Kawamoto, T.; Fujimoto, K.; Noshiro, M.; Seino, H.; Morohashi, S.; Kato, Y.; Kijima, H. BHLH transcription factor DEC2 regulates pro-apoptotic factor Bim in human oral cancer HSC-3 cells. Biomed. Res., 2012, 33(2), 75-82.
109. Wang, J.; Zhou, J.Y.; Wu, G.S. Bim protein degradation contributes to cisplatin resistance. J. Biol. Chem., 2011, 286(25), 22384-22392.
110. Wheate, N.J.; Walker, S.; Craig, G.E.; Oun, R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans., 2010, 39(35), 8113-8127.
111. Lee, K.B.; Byun, H.J.; Park, S.H.; Park, C.Y.; Lee, S.H.; Rho, S.B. CYR61 controls p53 and NF-kappaB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett., 2012, 315(1), 86-95.
112. Floros, K.V.; Thomadaki, H.; Katsaros, N.; Talieri, M.; Scorilas, A. mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol. Chem., 2004, 385(11), 1099-1103.
113. Wang, X.; Li, M.; Wang, J.; Yeung, C.M.; Zhang, H.; Kung, H.F.; Jiang, B.; Lin, M.C. The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells. Biochem. Pharmacol., 2006, 71(11), 1540-1550.
114. Hayward, R.L.; Macpherson, J.S.; Cummings, J.; Monia, B.P.; Smyth, J.F.; Jodrell, D.I. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. Mol. Cancer Ther., 2004, 3(2), 169-178.
115. Wang, Z.; Zhou, J.; Fan, J.; Qiu, S.J.; Yu, Y.; Huang, X.W.; Sun, J.; Tan, C.J.; Dai, Z. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Exp. Opin. Investig. Drugs, 2009, 18(11), 1595-1604.
116. Ngan, C.Y.; Yamamoto, H.; Takagi, A.; Fujie, Y.; Takemasa, I.; Ikeda, M.; Takahashi-Yanaga, F.; Sasaguri, T.; Sekimoto, M.; Matsuura, N.; Monden, M. Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci., 2008, 99(1), 129-139.
117. Peters, G.J.; Van der Wilt, C.L.; Van Moorsel, C.J.; Kroep, J.R.; Bergman, A.M.; Ackland, S.P. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol. Ther., 2000, 87(2-3), 227-253.
118. Wright, D.L.; Anderson, A.C. Antifolate agents: a patent review (2006 - 2010). Exp. Opin. Therap. Patents, 2011, 21(9), 1293-1308.
119. Juliusson, G.; Liliemark, J. Purine analogues: rationale for development, mechanisms of action, and pharmacokinetics in hairy cell leukemia. Hematol. Oncol. Clin. North Am., 2006, 20(5), 1087-1097.
120. Daher, G.C.; Harris, B.E.; Diasio, R.B. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol. Ther., 1990, 48(2), 189-222.
121. Da Silva, C.P.; De Oliveira, C.R.; Da Conceicao, M.; De Lima, P. Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes. Biochem. Pharmacol., 1996, 51(10), 1331-1340.
122. Kaufmann, S.H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res., 1989, 49(21), 5870-5878.
123. Floros, K.V.; Talieri, M.; Scorilas, A. Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol. Chem., 2006, 387(12), 1629-1633.
124. Simonian, P.L.; Grillot, D.A.; Nunez, G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood, 1997, 90(3), 1208-1216.
125. Chen, Y.X.; Lv, W.G.; Chen, H.Z.; Ye, F.; Xie, X. Methotrexate induces apoptosis of human choriocarcinoma cell line JAR via a mitochondrial pathway. Eur. J. Obstetrics, Gynecol. Reprod. Biol., 2009, 143(2), 107-111.
126. Taylor, E.C.; Kuhnt, D.; Shih, C.; Rinzel, S.M.; Grindey, G.B.; Barredo, J.; Jannatipour, M.; Moran, R.G. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J. Med. Chem., 1992, 35(23), 4450-4454.
127. Yang, T.Y.; Chang, G.C.; Chen, K.C.; Hung, H.W.; Hsu, K.H.; Wu, C.H.; Sheu, G.T.; Hsu, S.L. Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways. Mol. Carcinog., 2013, 52(3), 183-194.
128. Buque, A.; Muhialdin, J.S.; Munoz, A.; Calvo, B.; Carrera, S.; Aresti, U.; Sancho, A.; Rubio, I.; Lopez-Vivanco, G. Molecular mechanism implicated in Pemetrexedinduced apoptosis in human melanoma cells. Mol. Cancer, 2012, 11(1), 25.
129. Ogawa, K.; Shichishima, T.; Nakamura, N.; Maruyama, Y. Induction of apoptosis in vivo and in vitro in hairy cell leukemia treated by deoxycoformycin. The Tohoku J. Exp. Med., 2000, 192(1), 87-98.
130. Awan, F.T.; Kay, N.E.; Davis, M.E.; Wu, W.; Geyer, S.M.; Leung, N.; Jelinek, D.F.; Tschumper, R.C.; Secreto, C.R.; Lin, T.S.; Grever, M.R.; Shanafelt, T.D.; Zent, C.S.; Call, T.G.; Heerema, N.A.; Lozanski, G.; Byrd, J.C.; Lucas, D.M. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood, 2009, 113(3), 535-537.
131. Else, M.; Dearden, C.E.; Matutes, E.; Garcia-Talavera, J.; Rohatiner, A.Z.; Johnson, S.A.; O'Connor, N.T.; Haynes, A.; Osuji, N.; Forconi, F.; Lauria, F.; Catovsky, D. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br. J. Haematol., 2009, 145(6), 733-740.
132. Kantarjian, H.M.; Estey, E.H.; Keating, M.A. New chemotherapeutic agents in acute myeloid leukemia. Leukemia, 1996, 10(Suppl 1), S4-6.
133. Marzo, I.; Perez-Galan, P.; Giraldo, P.; Rubio-Felix, D.; Anel, A.; Naval, J. Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and independent pathways acting on mitochondria. Biochem. J., 2001, 359(Pt 3), 537-546.
134. Petersen, A.J.; Brown, R.D.; Gibson, J.; Pope, B.; Luo, X.F.; Schutz, L.; Wiley, J.S.; Joshua, D.E. Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro. Eur. J. Haematol., 1996, 56(4), 213-220.
135. Morales, A.A.; Olsson, A.; Celsing, F.; Osterborg, A.; Jondal, M.; Osorio, L.M. High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int. J. Cancer, 2005, 113(5), 730-737.
136. Liu, H.B.; Zhang, M.; Li, C.L.; He, P.C. Effect of clofarabine on proliferation and Bcl-2 expression of NB4 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2012, 20(3), 571-573.
137. Takahashi, T.; Shimizu, M.; Akinaga, S. Mechanisms of the apoptotic activity of Cl-F-araA in a human T-ALL cell line, CCRF-CEM. Cancer Chemother. Pharmacol., 2002, 50(3), 193-201.
138. Posovszky, C.; Friesen, C.; Herr, I.; Debatin, K.M. Chemotherapeutic drugs sensitize pre-B ALL cells for CD95 and cytotoxic T-lymphocyte-mediated apoptosis. Leukemia, 1999, 13(3), 400-409.
139. Balkham, S.E.; Sargent, J.M.; Elgie, A.W.; Williamson, C.J.; Taylor, C.G. Comparison of BCL-2 and BAX protein expression with in vitro sensitivity to ARA-C and 6TG in AML. Adv. Exp. Med. Biol., 1999, 457, 335-340.
140. Salomons, G.S.; Brady, H.J.; Verwijs-Janssen, M.; Van Den Berg, J.D.; Hart, A.A.; Van Den Berg, H.; Behrendt, H.; Hahlen, K.; Smets, L.A. The Bax alpha: Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int. J. Cancer, 1997, 71(6), 959-965.
141. Jarmula, A. Antifolate inhibitors of thymidylate synthase as anticancer drugs. Mini Rev. Med. Chem., 2010, 10(13), 1211-1222.
142. Korbakis, D.; Scorilas, A. Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12. Tumour Biol., 2009, 30(2), 100-107.
143. Hernandez-Vargas, H.; Ballestar, E.; Carmona-Saez, P.; Von Kobbe, C.; Banon-Rodriguez, I.; Esteller, M.; Moreno-Bueno, G.; Palacios, J. Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int. J. Cancer, 2006, 119(5), 1164-1175.
144. Klubes, P.; Cerna, I.; Meldon, M.A. Effect of concurrent calcium leucovorin infusion on 5-fluorouracil cytotoxicity against murine L1210 leukemia. Cancer Chemother. Pharmacol., 1981, 6(2), 121-125.
145. El Sayed, Y.M.; Sadee, W. Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes. Cancer Res., 1983, 43(9), 4039-4044.
146. Ishikawa, T.; Utoh, M.; Sawada, N.; Nishida, M.; Fukase, Y.; Sekiguchi, F.; Ishitsuka, H. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem. Pharmacol., 1998, 55(7), 1091-1097.
147. Ismaili, N. Treatment of colorectal liver metastases. World J. Surg. Oncol., 2011, 9, 154.
148. O'Shaughnessy, J.A.; Kaufmann, M.; Siedentopf, F.; Dalivoust, P.; Debled, M.; Robert, N.J.; Harbeck, N. Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist, 2012, 17(4), 476-484.
149. Chefrour, M.; Milano, G.; Formento, P.; Giacometti, S.; Denden, A.; Renee, N.; Iliadis, A.; Fischel, J.L.; Ciccolini, J. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants. Fundamen. Clin. Pharmacol., 2012, 26(4), 530-537.
150. Matsuura, T.; Fukuda, Y.; Fujitaka, T.; Nishisaka, T.; Sakatani, T.; Ito, H. Preoperative treatment with tegafur suppositories enhances apoptosis and reduces the intratumoral microvessel density of human colorectal carcinoma. Cancer, 2000, 88(5), 1007-1015.
151. Suzuki, K.; Kazui, T.; Yoshida, M.; Uno, T.; Kobayashi, T.; Kimura, T.; Yoshida, T.; Sugimura, H. Drug-induced apoptosis and p53, BCL-2 and BAX expression in breast cancer tissues in vivo and in fibroblast cells in vitro. Jap. J. Clin. Oncol., 1999, 29(7), 323-331.
152. Kottke, T.J.; Blajeski, A.L.; Martins, L.M.; Mesner, P.W., Jr.; Davidson, N.E.; Earnshaw, W.C.; Armstrong, D.K.; Kaufmann, S.H. Comparison of paclitaxel-, 5-fluoro-2'-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis. J. Biol. Chem., 1999, 274(22), 15927-15936.
153. Wang, S.; Liu, Q.; Zhang, Y.; Liu, K.; Yu, P.; Luan, J.; Duan, H.; Lu, Z.; Wang, F.; Wu, E.; Yagasaki, K.; Zhang, G. Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action. Mol. Cancer, 2009, 8, 81.
154. Kohrt, H.E.; Patel, S.; Ho, M.; Owen, T.; Pollyea, D.A.; Majeti, R.; Gotlib, J.; Coutre, S.; Liedtke, M.; Berube, C.; Alizadeh, A.A.; Medeiros, B.C. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. Am. J. Hematol., 2010, 85(11), 877-881.
155. Seif, A.E.; Reilly, A.F.; Rheingold, S.R. Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature. J. Pediatric. Hematol. Oncol., 2010, 32(8), e349-352.
156. Wang, W.S.; Tzeng, C.H.; Chiou, T.J.; Liu, J.H.; Hsieh, R.K.; Yen, C.C.; Chen, P.M. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. Jap. J. Clin. Oncol., 1997, 27(3), 154-157.
157. Avramis, V.I.; Nandy, P.; Kwock, R.; Solorzano, M.M.; Mukherjee, S.K.; Danenberg, P.; Cohen, L.J. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. Anticancer Res., 1998, 18(4A), 2327-2338.
158. De Vries, J.F.; Falkenburg, J.H.; Willemze, R.; Barge, R.M. The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells. Haematologica, 2006, 91(7), 912-919.
159. Cerqueira, N.M.; Fernandes, P.A.; Ramos, M.J. Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry, 2007, 13(30), 8507-8515.
160. Hussain, A.; Brahmbhatt, K.; Priyani, A.; Ahmed, M.; Rizvi, T.A.; Sharma, C. Eugenol enhances the chemotherapeutic potential of gemcitabine and induces anticarcinogenic and anti-inflammatory activity in human cervical cancer cells. Cancer Biother. Radiopharm., 2011, 26(5), 519-527.
161. Jeon, H.G.; Yoon, C.Y.; Yu, J.H.; Park, M.J.; Lee, J.E.; Jeong, S.J.; Hong, S.K.; Byun, S.S.; Lee, S.E. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-kappaB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells. J. Urol., 2011, 186(5), 2084-2093.
162. Dong, J.; Zhao, Y.P.; Zhou, L.; Zhang, T.P.; Chen, G. Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Arch. Med. Res., 2011, 42(1), 8-14.
163. Kantarjian, H.; Issa, J.P.; Rosenfeld, C.S.; Bennett, J.M.; Albitar, M.; DiPersio, J.; Klimek, V.; Slack, J.; De Castro, C.; Ravandi, F.; Helmer, R., 3rd; Shen, L.; Nimer, S.D.; Leavitt, R.; Raza, A.; Saba, H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer, 2006, 106(8), 1794-1803.
164. Kantarjian, H.M.; O'Brien, S.; Cortes, J.; Giles, F.J.; Faderl, S.; Issa, J.P.; Garcia-Manero, G.; Rios, M.B.; Shan, J.; Andreeff, M.; Keating, M.; Talpaz, M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer, 2003, 98(3), 522-528.
165. Bogdanovic, G.; Jurisic, V.; Kraguljac, N.; Mrdjanovic, J.; Jakimov, D.; Krtolica, K.; Krajnovic, M.; Magic, Z.; Stojiljkovic, B.; Andrijevic, L.; Srdic, T.; Baltic, M.; Popovic, S. Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome. Leuk. Res., 2007, 31(8), 1097-1105.
166. Stankov, K.; Bogdanovic, G.; Kojic, V.; Stankov, S.; Jojic, N.; Popovic, L.; Popovic, S. Expression analysis of genes involved in epigenetic regulation and apoptosis in human malignant haematopoietic cell lines treated with 5-azacytidine. J. BUON, 2011, 16(1), 116-122.
167. Yagi, S.; Oda-Sato, E.; Uehara, I.; Asano, Y.; Nakajima, W.; Takeshita, T.; Tanaka, N. 5-Aza-2'-deoxycytidine restores proapoptotic function of p53 in cancer cells resistant to p53-induced apoptosis. Cancer Invest., 2008, 26(7), 680-688.
168. Yi, T.Z.; Li, J.; Han, X.; Guo, J.; Qu, Q.; Guo, L.; Sun, H.D.; Tan, W.H. DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo. Chemotherapy, 2012, 58(1), 19-29.
169. Cluzeau, T.; Robert, G.; Mounier, N.; Karsenti, J.M.; Dufies, M.; Puissant, A.; Jacquel, A.; Renneville, A.; Preudhomme, C.; Cassuto, J.P.; Raynaud, S.; Luciano, F.; Auberger, P. BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget, 2012, 3(4), 490-501.
170. Alagoz, M.; Gilbert, D.C.; El-Khamisy, S.; Chalmers, A.J. DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Curr. Med. Chem., 2012, 19(23), 3874-3885.
171. Xu, H.; Lv, M.; Tian, X. A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007. Curr. Med. Chem., 2009, 16(3), 327-349.
172. Kizek, R.; Adam, V.; Hrabeta, J.; Eckschlager, T.; Smutny, S.; Burda, J.V.; Frei, E.; Stiborova, M. Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances. Pharmacol. Ther., 2012, 133(1), 26-39.
173. Fry, D.W. Biochemical pharmacology of anthracenediones and anthrapyrazoles. Pharmacol. Ther., 1991, 52(1), 109-125.
174. Andre, T.; Louvet, C.; Maindrault-Goebel, F.; Couteau, C.; Mabro, M.; Lotz, J.P.; Gilles-Amar, V.; Krulik, M.; Carola, E.; Izrael, V.; De Gramont, A. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur. J. Cancer, 1999, 35(9), 1343-1347.
175. Gupta, V.; Su, Y.S.; Samuelson, C.G.; Liebes, L.F.; Chamberlain, M.C.; Hofman, F.M.; Schonthal, A.H.; Chen, T.C. Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J. Neurosurg., 2007, 106(3), 455-462.
176. Oizumi, S.; Isobe, H.; Ogura, S.; Ishida, T.; Yamazaki, K.; Nishimura, M.; Kawakami, Y.; Dosaka-Akita, H. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells. Anticancer Res., 2002, 22(6C), 4029-4037.
177. Takeba, Y.; Kumai, T.; Matsumoto, N.; Nakaya, S.; Tsuzuki, Y.; Yanagida, Y.; Kobayashi, S. Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis. J. Pharmacol. Sci., 2007, 104(3), 232-242.
178. Takeba, Y.; Sekine, S.; Kumai, T.; Matsumoto, N.; Nakaya, S.; Tsuzuki, Y.; Yanagida, Y.; Nakano, H.; Asakura, T.; Ohtsubo, T.; Kobayashi, S. Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. Biol. Pharm. Bull., 2007, 30(8), 1400-1406.
179. Zhang, J.; Cheng, C.; He, C.L.; Zhou, Y.J.; Cao, Y. The expression of Bcl-XL, Bcl-XS and p27Kip1 in topotecan-induced apoptosis in hepatoblastoma HepG2 cell line. Cancer Invest., 2008, 26(5), 456-463.
180. Winter, S.; Weller, M. Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression. J. Pharmacol. Exp. Therap., 1998, 286(3), 1374-1382.
181. Leung, L.K.; Wang, T.T. Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7. Breast Cancer Res. Treat., 1999, 55(1), 73-83.
182. Floros, K.V.; Thomadaki, H.; Florou, D.; Talieri, M.; Scorilas, A. Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. Ann. N Y Acad. Sci., 2006, 1090, 89-97.
183. Fukumi, S.; Horiguchi-Yamada, J.; Nakada, S.; Nagai, M.; Ohno, T.; Yamada, H. Differential responses of Bcl-2 family genes to etoposide in chronic myeloid leukemia K562 cells. Mol. Cell Biochem., 2000, 206(1-2), 43-50.
184. Miao, L.; Yi, P.; Wang, Y.; Wu, M. Etoposide upregulates Bax-enhancing tumour necrosis factor-related apoptosis inducing ligand-mediated apoptosis in the human hepatocellular carcinoma cell line QGY-7703. Eur. J. Biochem., 2003, 270(13), 2721-2731.
185. Zhang, F.; Xu, L.; Qu, X.; Zhao, M.; Jin, B.; Kang, J.; Liu, Y.; Hu, X. Synergistic antitumor effect of beta-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells. Mol. Med. Rep., 2011, 4(6), 1189-1193.
186. Quillet-Mary, A.; Mansat, V.; Duchayne, E.; Come, M.G.; Allouche, M.; Bailly, J.D.; Bordier, C.; Laurent, G. Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia, 1996, 10(3), 417-425.
187. Allouche, M.; Bettaieb, A.; Vindis, C.; Rousse, A.; Grignon, C.; Laurent, G. Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells. Oncogene, 1997, 14(15), 1837-1845.
188. Kim, Y.H.; Park, J.W.; Lee, J.Y.; Surh, Y.J.; Kwon, T.K. Bcl-2 overexpression prevents daunorubicin-induced apoptosis through inhibition of XIAP and Akt degradation. Biochem. Pharmacol., 2003, 66(9), 1779-1786.
189. Li, H.; Hui, L.; Xu, W. miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim. Et Biophysica Sinica, 2012, 44(3), 269-277.
190. Rao, J.; Xu, D.R.; Zheng, F.M.; Long, Z.J.; Huang, S.S.; Wu, X.; Zhou, W.H.; Huang, R.W.; Liu, Q., Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. J. Trans. Med., 2011, 9, 71.
191. Wu, X.X.; Mizutani, Y.; Kakehi, Y.; Yoshida, O.; Ogawa, O. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin. Cancer Res., 2000, 60(11), 2912-2918.
192. Lo, Y.L.; Ho, C.T.; Tsai, F.L. Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin. Eur. J. Pharmaceut. Sci., 2008, 35(1-2), 52-67.
193. Jin, X.; Wu, X.X.; Jin, C.; Inui, M.; Sugimoto, M.; Kakehi, Y. Delineation of apoptotic genes for synergistic apoptosis of lexatumumab and anthracyclines in human renal cell carcinoma cells by polymerase chain reaction array. Anticancer Drugs, 2012, 23(4), 445-454.
194. Liu, S.Y.; Song, S.X.; Lin, L.; Liu, X. Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin in a human osteosarcoma cell line. Chemotherapy, 2010, 56(2), 101-107.
195. Garcia-Manero, G.; Tambaro, F.P.; Bekele, N.B.; Yang, H.; Ravandi, F.; Jabbour, E.; Borthakur, G.; Kadia, T.M.; Konopleva, M.Y.; Faderl, S.; Cortes, J.E.; Brandt, M.; Hu, Y.; McCue, D.; Newsome, W.M.; Pierce, S.R.; De Lima, M.; Kantarjian, H.M. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J. Clin. Oncol., 2012, 30(18), 2204-2210.
196. Majlessipour, F.; Avramis, I.A.; Kwock, R.; Weinberg, K.I.; Avrami, V.I. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines. Anticancer Res., 2002, 22(3), 1361-1368.
197. Durrieu, F.; Belaud-Rotureau, M.A.; Lacombe, F.; Dumain, P.; Reiffers, J.; Boisseau, M.R.; Bernard, P.; Belloc, F. Synthesis of Bcl-2 in response to anthracycline treatment may contribute to an apoptosis-resistant phenotype in leukemic cell lines. Cytometry, 1999, 36(2), 140-149.
198. Andersen, S.M.; Rosada, C.; Dagnaes-Hansen, F.; Laugesen, I.G.; De Darko, E.; Dam, T.N.; Stenderup, K. Topical application of valrubicin has a beneficial effect on developing skin tumors. Carcinogenesis, 2010, 31(8), 1483-1490.
199. Lehman, T.A.; Modali, R.; Boukamp, P.; Stanek, J.; Bennett, W.P.; Welsh, J.A.; Metcalf, R.A.; Stampfer, M.R.; Fusenig, N.; Rogan, E.M.; Harris, C.C. p53 mutations in human immortalized epithelial cell lines. Carcinogenesis, 1993, 14(5), 833-839.
200. Brana, M.F.; Cacho, M.; Gradillas, A.; De Pascual-Teresa, B.; Ramos, A. Intercalators as anticancer drugs. Curr Pharm Des, 2001, 7(17), 1745-1780.
201. Hollstein, U.; Breitmaier, E.; Jung, G. 13-C nuclear jagnetic resonance study of actinomycin D. J. Am. Chem. Soc., 1974, 96(26), 8036-8040.
202. Kleeff, J.; Kornmann, M.; Sawhney, H.; Korc, M. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. Int J. Cancer, 2000, 86(3), 399-407.
203. Mori, S.; Murakami-Mori, K.; Nakamura, S.; Ashkenazi, A.; Bonavida, B. Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D. J. Immunol., 1999, 162(9), 5616-5623.
204. Ng, C.P.; Zisman, A.; Bonavida, B. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate, 2002, 53(4), 286-299.
205. Xu, H.; Krystal, G.W. Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines. Clin. Cancer Res., 2010, 16(17), 4392-4400.
206. Wang, K.R.; Zhang, B.Z.; Zhang, W.; Yan, J.X.; Li, X.; Wang, R. Potent antitumor effects of a novel actinomycin D analog Leu5AMD. Cancer Lett., 2008, 268(1), 38-45.
207. Chen, Y.; Liu, J.; Yuan, B.; Cao, C.; Qin, S.; Cao, X.; Bian, G.; Wang, Z.; Jiang, J. Methylated actinomycin D, a novel actinomycin D analog induces apoptosis in HepG2 cells through fas- and mitochondria-mediated pathways. Mol. Carcinog., 2013, 52(12), 983-986.
208. Seitz, S.J.; Schleithoff, E.S.; Koch, A.; Schuster, A.; Teufel, A.; Staib, F.; Stremmel, W.; Melino, G.; Krammer, P.H.; Schilling, T.; Muller, M. Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int. J. Cancer, 2010, 126(9), 2049-2066.
209. Liang, H.; Zhan, H.J.; Wang, B.G.; Pan, Y.; Hao, X.S. Change in expression of apoptosis genes after hyperthermia, chemotherapy and radiotherapy in human colon cancer transplanted into nude mice. World J. Gastroenterol., 2007, 13(32), 4365-4371.
210. Ma, L.; Xie, Y.L.; Yu, Y.; Zhang, Q.N. Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac. World J. Gastroenterol., 2005, 11(12), 1829-1832.
211. Emi, M.; Kim, R.; Tanabe, K.; Uchida, Y.; Toge, T. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res., 2005, 7(6), R940-952.
212. Green, M.R. Targeting targeted therapy. N Engl J Med, 2004, 350(21), 2191-2193.
213. Waldmann, T.A. Immunotherapy: past, present and future. Nat. Med., 2003, 9(3), 269-277.
214. Prewett, M.; Rockwell, P.; Rockwell, R.F.; Giorgio, N.A.; Mendelsohn, J.; Scher, H.I.; Goldstein, N.I. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J. Immunotherapy Emphasis Tumor Immunol., 1996, 19(6), 419-427.
215. Peeters, M.; Price, T.; Van Laethem, J.L. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Oncologist, 2009, 14(1), 29-39.
216. Mesia, R.; Rivera, F.; Kawecki, A.; Rottey, S.; Hitt, R.; Kienzer, H.; Cupissol, D.; De Raucourt, D.; Benasso, M.; Koralewski, P.; Delord, J.P.; Bokemeyer, C.; Curran, D.; Gross, A.; Vermorken, J.B. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann. Oncol., 2010, 21(10), 1967-1973.
217. Huang, S.M.; Bock, J.M.; Harari, P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res., 1999, 59(8), 1935-1940.
218. Takaoka, S.; Iwase, M.; Uchida, M.; Yoshiba, S.; Kondo, G.; Watanabe, H.; Ohashi, M.; Nagumo, M.; Shintani, S. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells. Int. J. Oncol., 2007, 30(6), 1469-1476.
219. Xu, F.; Tian, Y.; Huang, Y.; Zhang, L.L.; Guo, Z.Z.; Huang, J.J.; Lin, T.Y. EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis. Chin. J. Cancer, 2011, 30(10), 701-711.
220. Schulze-Bergkamen, H.; Ehrenberg, R.; Hickmann, L.; Vick, B.; Urbanik, T.; Schimanski, C.C.; Berger, M.R.; Schad, A.; Weber, A.; Heeger, S.; Galle, P.R.; Moehler, M. Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J. Gastroenterol., 2008, 14(24), 3829-3840.
221. Huang, Z.Q.; Buchsbaum, D.J.; Raisch, K.P.; Bonner, J.A.; Bland, K.I.; Vickers, S.M. Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. J. Surg. Res., 2003, 111(2), 274-283.
222. McNeil, C. Herceptin raises its sights beyond advanced breast cancer. J. Natl. Cancer Inst., 1998, 90(12), 882-883.
223. Bang, Y.J.; Van Cutsem, E.; Feyereislova, A.; Chung, H.C.; Shen, L.; Sawaki, A.; Lordick, F.; Ohtsu, A.; Omuro, Y.; Satoh, T.; Aprile, G.; Kulikov, E.; Hill, J.; Lehle, M.; Ruschoff, J.; Kang, Y.K. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742), 687-697.
224. Santin, A.D.; Bellone, S.; Roman, J.J.; McKenney, J.K.; Pecorelli, S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int. J. Gynaecol. Obstet., 2008, 102(2), 128-131.
225. Milella, M.; Trisciuoglio, D.; Bruno, T.; Ciuffreda, L.; Mottolese, M.; Cianciulli, A.; Cognetti, F.; Zangemeister-Wittke, U.; Del Bufalo, D.; Zupi, G. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells. Clin. Cancer Res., 2004, 10(22), 7747-7756.
226. Kim, R.; Tanabe, K.; Emi, M.; Uchida, Y.; Toge, T. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells. Cancer, 2005, 103(10), 2199-2207.
227. Henson, E.S.; Hu, X.; Gibson, S.B. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin. Cancer Res., 2006, 12(3 Pt 1), 845-853.
228. Chen, H.X.; Gore-Langton, R.E.; Cheson, B.D. Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology, 2001, 15(8), 1017, 1020, 1023-1016.
229. Small, A.C.; Oh, W.K. Bevacizumab treatment of prostate cancer. Exp. Opin. Biol. Therapy, 2012, 12(9), 1241-1249.
230. Eskens, F.A.; Sleijfer, S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eur. J. Cancer, 2008, 44(16), 2350-2356.
231. Wang, Y.; Dong, L.; Bi, Q.; Ge, X.; Zhang, X.; Wu, D.; Fu, J.; Zhang, C.; Wang, C.; Li, S. Beyond antiangiogenesis: intratumorally injected bevacizumab plays a cisplatin-sensitizing role in squamous cell carcinomas in mice. Chemotherapy, 2011, 57(3), 244-252.
232. Anai, S.; Sakamoto, N.; Sakai, Y.; Tanaka, M.; Porvasnik, S.; Urbanek, C.; Cao, W.; Goodison, S.; Rosser, C.J. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer. Urol. Oncol., 2011, 29(4), 421-429.
233. Cramer, P.; Hallek, M. Hematological cancer in 2011: New therapeutic targets and treatment strategies. Nature reviews. Clin. Oncol., 2012, 9(2), 72-74.
234. Hou, Y.; Wang, H.Q.; Ba, Y. Effects of CDC7 gene silencing and Rituximab on apoptosis in diffuse large B cell lymphoma cells. J. Cancer Res. Clin. Oncol., 2012, 138(12), 2027-2034.
235. Olejniczak, S.H.; Hernandez-Ilizaliturri, F.J.; Clements, J.L.; Czuczman, M.S. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin. Cancer Res., 2008, 14(5), 1550-1560.
236. Bonavida, B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene, 2007, 26(25), 3629-3636.
237. Alas, S.; Bonavida, B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res., 2001, 61(13), 5137-5144.
238. Jazirehi, A.R.; Gan, X.H.; De Vos, S.; Emmanouilides, C.; Bonavida, B. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol. Cancer Ther., 2003, 2(11), 1183-1193.
239. Zhang, H.Y.; Chen, H.T.; Peng, P.J. Rituximab-mediated sensitization of B-NHL cell lines to apoptosis induced by gemcitabine and Navelbine in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2010, 18(4), 873-876.
240. Tzifi, F.; Economopoulou, C.; Gourgiotis, D.; Ardavanis, A.; Papageorgiou, S.; Scorilas, A. The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias. Adv. Hematol., 2012, 2012, 524308.
241. Stolz, C.; Hess, G.; Hahnel, P.S.; Grabellus, F.; Hoffarth, S.; Schmid, K.W.; Schuler, M. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood, 2008, 112(8), 3312-3321.
242. Hussain, S.R.; Cheney, C.M.; Johnson, A.J.; Lin, T.S.; Grever, M.R.; Caligiuri, M.A.; Lucas, D.M.; Byrd, J.C. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin. Cancer Res., 2007, 13(7), 2144-2150.
243. Brien, G.; Trescol-Biemont, M.C.; Bonnefoy-Berard, N. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene, 2007, 26(39), 5828-5832.
244. Osherov, N.; Gazit, A.; Gilon, C.; Levitzki, A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J. Biol. Chem., 1993, 268(15), 11134-11142.
245. Gazit, A.; Osherov, N.; Posner, I.; Yaish, P.; Poradosu, E.; Gilon, C.; Levitzki, A. Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J. Med. Chem., 1991, 34(6), 1896-1907.
246. Yaish, P.; Gazit, A.; Gilon, C.; Levitzki, A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science, 1988, 242(4880), 933-935.
247. Pajares, B.; Torres, E.; Trigo, J.M.; Saez, M.I.; Ribelles, N.; Jimenez, B.; Alba, E. Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. Clin. Trans. Oncol., 2012, 14(2), 94-101.
248. Ohanian, M.; Cortes, J.; Kantarjian, H.; Jabbour, E. Tyrosine kinase inhibitors in acute and chronic leukemias. Exp. Opin. Pharmacother., 2012, 13(7), 927-938.
249. Ciardiello, F.; Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res., 2001, 7(10), 2958-2970.
250. Ciardiello, F.; Caputo, R.; Damiano, V.; Troiani, T.; Vitagliano, D.; Carlomagno, F.; Veneziani, B.M.; Fontanini, G.; Bianco, A.R.; Tortora, G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res., 2003, 9(4), 1546-1556.
251. Deng, J.; Shimamura, T.; Perera, S.; Carlson, N.E.; Cai, D.; Shapiro, G.I.; Wong, K.K.; Letai, A. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res., 2007, 67(24), 11867-11875.
252. Gong, Y.; Somwar, R.; Politi, K.; Balak, M.; Chmielecki, J.; Jiang, X.; Pao, W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med., 2007, 4(10), e294.
253. Konishi, J.; Yi, F.; Chen, X.; Vo, H.; Carbone, D.P.; Dang, T.P. Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. Oncogene, 2010, 29(4), 589-596.
254. Lu, Y.Y.; Jing, D.D.; Xu, M.; Wu, K.; Wang, X.P. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World J. Gastroenterol., 2008, 14(35), 5403-5411.
255. Costa, D.B.; Halmos, B.; Kumar, A.; Schumer, S.T.; Huberman, M.S.; Boggon, T.J.; Tenen, D.G.; Kobayashi, S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med., 2007, 4(10), 1669-1679; discussion 1680.
256. Cragg, M.S.; Kuroda, J.; Puthalakath, H.; Huang, D.C.; Strasser, A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med., 2007, 4(10), 1681-1689; discussion 1690.
257. Sarkar, S.; Mazumdar, A.; Dash, R.; Sarkar, D.; Fisher, P.B.; Mandal, M. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol. Ther., 2010, 9(8), 592-603.
258. Sarkar, S.; Mazumdar, A.; Dash, R.; Sarkar, D.; Fisher, P.B.; Mandal, M. ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. J. Cell Physiol., 2011, 226(2), 375-384.
259. Thornton, K.; Kim, G.; Maher, V.E.; Chattopadhyay, S.; Tang, S.; Moon, Y.J.; Song, P.; Marathe, A.; Balakrishnan, S.; Zhu, H.; Garnett, C.; Liu, Q.; Booth, B.; Gehrke, B.; Dorsam, R.; Verbois, L.; Ghosh, D.; Wilson, W.; Duan, J.; Sarker, H.; Miksinski, S.P.; Skarupa, L.; Ibrahim, A.; Justice, R.; Murgo, A.; Pazdur, R. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin. Cancer Res., 2012, 18(14), 3722-3730.
260. Deshpande, H.; Roman, S.; Thumar, J.; Sosa, J.A. Vandetanib (ZD6474) in the treatment of medullary thyroid cancer. Clin. Med. Insight. Oncol., 2011, 5, 213-221.
261. Sun, Z.J.; Chen, G.; Hu, X.; Zhang, W.; Liu, Y.; Zhu, L.X.; Zhou, Q.; Zhao, Y.F. Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin. Apoptosis, 2010, 15(7), 850-863.
262. Crawford, A.; Nahta, R. Targeting Bcl-2 in herceptin-resistant breast cancer cell lines. Curr. Pharmacog. Person. Med., 2011, 9(3), 184-190.
263. Cruickshanks, N.; Hamed, H.A.; Bareford, M.D.; Poklepovic, A.; Fisher, P.B.; Grant, S.; Dent, P. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Mol. Pharmacol., 2012, 81(5), 748-758.
264. Witters, L.M.; Witkoski, A.; Planas-Silva, M.D.; Berger, M.; Viallet, J.; Lipton, A. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol. Rep., 2007, 17(2), 465-469.
265. Tang, Y.; Hamed, H.A.; Cruickshanks, N.; Fisher, P.B.; Grant, S.; Dent, P. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Mol. Pharmacol., 2012, 81(4), 527-540.
266. Martin, A.P.; Mitchell, C.; Rahmani, M.; Nephew, K.P.; Grant, S.; Dent, P. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol. Ther., 2009, 8(21), 2084-2096.
267. Valabrega, G.; Capellero, S.; Cavalloni, G.; Zaccarello, G.; Petrelli, A.; Migliardi, G.; Milani, A.; Peraldo-Neia, C.; Gammaitoni, L.; Sapino, A.; Pecchioni, C.; Moggio, A.; Giordano, S.; Aglietta, M.; Montemurro, F. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res. Treat., 2011, 130(1), 29-40.
268. Lang, J.Y.; Hsu, J.L.; Meric-Bernstam, F.; Chang, C.J.; Wang, Q.; Bao, Y.; Yamaguchi, H.; Xie, X.; Woodward, W.A.; Yu, D.; Hortobagyi, G.N.; Hung, M.C. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell, 2011, 20(3), 341-356.
269. Diaz, R.; Nguewa, P.A.; Parrondo, R.; Perez-Stable, C.; Manrique, I.; Redrado, M.; Catena, R.; Collantes, M.; Penuelas, I.; Diaz-Gonzalez, J.A.; Calvo, A. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer, 2010, 10, 188.
270. Olaussen, K.A.; Commo, F.; Tailler, M.; Lacroix, L.; Vitale, I.; Raza, S.Q.; Richon, C.; Dessen, P.; Lazar, V.; Soria, J.C.; Kroemer, G. Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene, 2009, 28(48), 4249-4260.
271. Goldman, J.M.; Melo, J.V. Chronic myeloid leukemia--advances in biology and new approaches to treatment. N. Engl. J. Med., 2003, 349(15), 1451-1464.
272. Blanke, C.D.; Demetri, G.D.; Von Mehren, M.; Heinrich, M.C.; Eisenberg, B.; Fletcher, J.A.; Corless, C.L.; Fletcher, C.D.; Roberts, P.J.; Heinz, D.; Wehre, E.; Nikolova, Z.; Joensuu, H. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol., 2008, 26(4), 620-625.
273. Krystal, G.W.; Honsawek, S.; Litz, J.; Buchdunger, E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res., 2000, 6(8), 3319-3326.
274. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344(14), 1031-1037.
275. Essafi, A.; De Mattos, F.S.; Hassen, Y.A.; Soeiro, I.; Mufti, G.J.; Thomas, N.S.; Medema, R.H.; Lam, E.W. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene, 2005, 24(14), 2317-2329.
276. Brunet, A.; Bonni, A.; Zigmond, M.J.; Lin, M.Z.; Juo, P.; Hu, L.S.; Anderson, M.J.; Arden, K.C.; Blenis, J.; Greenberg, M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 1999, 96(6), 857-868.
277. Demetri, G.D.; Von Mehren, M.; Blanke, C.D.; Van den Abbeele, A.D.; Eisenberg, B.; Roberts, P.J.; Heinrich, M.C.; Tuveson, D.A.; Singer, S.; Janicek, M.; Fletcher, J.A.; Silverman, S.G.; Silberman, S.L.; Capdeville, R.; Kiese, B.; Peng, B.; Dimitrijevic, S.; Druker, B.J.; Corless, C.; Fletcher, C.D.; Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med., 2002, 347(7), 472-480.
278. Yamamura, Y.; Lee, W.L.; Inoue, K.; Ida, H.; Ito, Y. RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J. Biol. Chem., 2006, 281(8), 5267-5276.
279. Kuroda, J.; Puthalakath, H.; Cragg, M.S.; Kelly, P.N.; Bouillet, P.; Huang, D.C.; Kimura, S.; Ottmann, O.G.; Druker, B.J.; Villunger, A.; Roberts, A.W.; Strasser, A. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc. Natl. Acad. Sci. USA, 2006, 103(40), 14907-14912.
280. Arunasree, K.M.; Roy, K.R.; Anilkumar, K.; Aparna, A.; Reddy, G.V.; Reddanna, P. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk. Res., 2008, 32(6), 855-864.
281. Wei, Y.L.; Xu, L.; Liang, Y.; Xu, X.H.; Zhao, X.Y. Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo. Acta Pharmacol. Sin., 2009, 30(4), 451-457.
282. Shah, N.P.; Tran, C.; Lee, F.Y.; Chen, P.; Norris, D.; Sawyers, C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 2004, 305(5682), 399-401.
283. Foa, R.; Vitale, A.; Vignetti, M.; Meloni, G.; Guarini, A.; De Propris, M.S.; Elia, L.; Paoloni, F.; Fazi, P.; Cimino, G.; Nobile, F.; Ferrara, F.; Castagnola, C.; Sica, S.; Leoni, P.; Zuffa, E.; Fozza, C.; Luppi, M.; Candoni, A.; Iacobucci, I.; Soverini, S.; Mandelli, F.; Martinelli, G.; Baccarani, M. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 2011, 118(25), 6521-6528.
284. Yu, E.Y.; Wilding, G.; Posadas, E.M.; Gross, M.; Culine, S.; Massard, C.; Hudes, G.R.; Cheng, S.; Paliwal, P.; Sternberg, C.N. Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study. J. Clin. Oncol., 2008, 26(suppl), abstr 5156.
285. Twardowski, P.; Chen, C.; Kraft, A.S.; Chatta, G.S.; Alexson, E.; Mitsuhashi, M.; Ye, W.; Lilly, M. A phase II trial of dasatinib in subjects with hormone-refractory prostate cancer previously treated with chemotherapy. J. Clin. Oncol., 2011, 29(suppl), abstr 4575.
286. Schittenhelm, M.M.; Shiraga, S.; Schroeder, A.; Corbin, A.S.; Griffith, D.; Lee, F.Y.; Bokemeyer, C.; Deininger, M.W.; Druker, B.J.; Heinrich, M.C. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res., 2006, 66(1), 473-481.
287. Condorelli, F.; Genazzani, A.A. Dasatinib: is it all in the dose? BioDrugs, 2010, 24(3), 157-163.
288. Nguyen, T.K.; Rahmani, M.; Harada, H.; Dent, P.; Grant, S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood, 2007, 109(9), 4006-4015.
289. Golemovic, M.; Verstovsek, S.; Giles, F.; Cortes, J.; Manshouri, T.; Manley, P.W.; Mestan, J.; Dugan, M.; Alland, L.; Griffin, J.D.; Arlinghaus, R.B.; Sun, T.; Kantarjian, H.; Beran, M. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res., 2005, 11(13), 4941-4947.
290. Aichberger, K.J.; Mayerhofer, M.; Krauth, M.T.; Vales, A.; Kondo, R.; Derdak, S.; Pickl, W.F.; Selzer, E.; Deininger, M.; Druker, B.J.; Sillaber, C.; Esterbauer, H.; Valent, P. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res., 2005, 65(20), 9436-9444.
291. Belloc, F.; Moreau-Gaudry, F.; Uhalde, M.; Cazalis, L.; Jeanneteau, M.; Lacombe, F.; Praloran, V.; Mahon, F.X. Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. Cancer Biol. Ther., 2007, 6(6), 912-919.
292. Liu, Y.; Wang, Z.; Kwong, S.Q.; Lui, E.L.; Friedman, S.L.; Li, F.R.; Lam, R.W.; Zhang, G.C.; Zhang, H.; Ye, T. Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist nilotinib. J. Hepatol., 2011, 55(3), 612-625.
293. Golas, J.M.; Arndt, K.; Etienne, C.; Lucas, J.; Nardin, D.; Gibbons, J.; Frost, P.; Ye, F.; Boschelli, D.H.; Boschelli, F. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res., 2003, 63(2), 375-381.
294. Boschelli, F.; Arndt, K.; Gambacorti-Passerini, C. Bosutinib: A review of preclinical studies in chronic myelogenous leukaemia. Eur. J. Cancer, 2010, 46(10), 1781-1789.
295. Ghosh, A.K.; Secreto, C.; Boysen, J.; Sassoon, T.; Shanafelt, T.D.; Mukhopadhyay, D.; Kay, N.E. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood, 2011, 117(6), 1928-1937.
296. Kimura, S.; Naito, H.; Segawa, H.; Kuroda, J.; Yuasa, T.; Sato, K.; Yokota, A.; Kamitsuji, Y.; Kawata, E.; Ashihara, E.; Nakaya, Y.; Naruoka, H.; Wakayama, T.; Nasu, K.; Asaki, T.; Niwa, T.; Hirabayashi, K.; Maekawa, T. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood, 2005, 106(12), 3948-3954.
297. Kuroda, J.; Kimura, S.; Strasser, A.; Andreeff, M.; O'Reilly, L.A.; Ashihara, E.; Kamitsuji, Y.; Yokota, A.; Kawata, E.; Takeuchi, M.; Tanaka, R.; Tabe, Y.; Taniwaki, M.; Maekawa, T. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ., 2007, 14(9), 1667-1677.
298. Knapper, S.; Burnett, A.K.; Littlewood, T.; Kell, W.J.; Agrawal, S.; Chopra, R.; Clark, R.; Levis, M.J.; Small, D. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood, 2006, 108(10), 3262-3270.
299. Hexner, E.O.; Serdikoff, C.; Jan, M.; Swider, C.R.; Robinson, C.; Yang, S.; Angeles, T.; Emerson, S.G.; Carroll, M.; Ruggeri, B.; Dobrzanski, P. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood, 2008, 111(12), 5663-5671.
300. Miknyoczki, S.J.; Chang, H.; Klein-Szanto, A.; Dionne, C.A.; Ruggeri, B.A. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin. Cancer Res., 1999, 5(8), 2205-2212.
301. Kim, K.T.; Levis, M.; Small, D. Constitutively activated FLT3 phosphorylates BAD partially through pim-1. Br. J. Haematol., 2006, 134(5), 500-509.
302. Darnell, J.E., Jr.; Kerr, I.M.; Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 1994, 264(5164), 1415-1421.
303. Joos, S.; Kupper, M.; Ohl, S.; von Bonin, F.; Mechtersheimer, G.; Bentz, M.; Marynen, P.; Moller, P.; Pfreundschuh, M.; Trumper, L.; Lichter, P. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res., 2000, 60(3), 549-552.
304. Gozgit, J.M.; Bebernitz, G.; Patil, P.; Ye, M.; Parmentier, J.; Wu, J.; Su, N.; Wang, T.; Ioannidis, S.; Davies, A.; Huszar, D.; Zinda, M. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J. Biol. Chem., 2008, 283(47), 32334-32343.
305. Amarante-Mendes, G.P.; McGahon, A.J.; Nishioka, W.K.; Afar, D.E.; Witte, O.N.; Green, D.R. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene, 1998, 16(11), 1383-1390.
306. Chu, W.S.; Aguilera, N.S.; Wei, M.Q.; Abbondanzo, S.L. Antiapoptotic marker Bcl-X(L), expression on Reed-Sternberg cells of Hodgkin's disease using a novel monoclonal marker, YTH-2H12. Hum. Pathol., 1999, 30(9), 1065-1070.
307. Diaz, T.; Navarro, A.; Ferrer, G.; Gel, B.; Gaya, A.; Artells, R.; Bellosillo, B.; Garcia-Garcia, M.; Serrano, S.; Martinez, A.; Monzo, M. Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. PLoS One, 2011, 6(4), e18856.
308. Forde, P.M.; Rudin, C.M. Crizotinib in the treatment of non-small-cell lung cancer. Exp. Opin. Pharmacother., 2012, 13(8), 1195-1201.
309. Carpenter, E.L.; Mosse, Y.P. Targeting ALK in neuroblastoma-preclinical and clinical advancements. Nat. Rev. Clin. Oncol., 2012, 9(7), 391-399.
310. Morgan, E.A.; Nascimento, A.F. Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma. Adv. Hematol., 2012, 2012, 529572.
311. Tanizaki, J.; Okamoto, I.; Okamoto, K.; Takezawa, K.; Kuwata, K.; Yamaguchi, H.; Nakagawa, K. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J. Thoracic Oncol., 2011, 6(10), 1624-1631.
312. Parry, D.; Guzi, T.; Shanahan, F.; Davis, N.; Prabhavalkar, D.; Wiswell, D.; Seghezzi, W.; Paruch, K.; Dwyer, M.P.; Doll, R.; Nomeir, A.; Windsor, W.; Fischmann, T.; Wang, Y.; Oft, M.; Chen, T.; Kirschmeier, P.; Lees, E.M. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol. Cancer Ther., 2010, 9(8), 2344-2353.
313. Fu, W.; Ma, L.; Chu, B.; Wang, X.; Bui, M.M.; Gemmer, J.; Altiok, S.; Pledger, W.J. The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells. Mol. Cancer Ther., 2011, 10(6), 1018-1027.
314. Wittmann, S.; Bali, P.; Donapaty, S.; Nimmanapalli, R.; Guo, F.; Yamaguchi, H.; Huang, M.; Jove, R.; Wang, H.G.; Bhalla, K. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res., 2003, 63(1), 93-99.
315. Dai, Y.; Rahmani, M.; Pei, X.Y.; Dent, P.; Grant, S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood, 2004, 104(2), 509-518.
316. Galmiche, A.; Ezzoukhry, Z.; Francois, C.; Louandre, C.; Sabbagh, C.; Nguyen-Khac, E.; Descamps, V.; Trouillet, N.; Godin, C.; Regimbeau, J.M.; Joly, J.P.; Barbare, J.C.; Duverlie, G.; Maziere, J.C.; Chatelain, D. BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. Mol. Cancer Res., 2010, 8(8), 1116-1125.
317. Lopez-Fauqued, M.; Gil, R.; Grueso, J.; Hernandez-Losa, J.; Pujol, A.; Moline, T.; Recio, J.A. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. Int. J. Cancer, 2010, 126(7), 1549-1561.
318. Guo, B.; Godzik, A.; Reed, J.C. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J. Biol. Chem., 2001, 276(4), 2780-2785.
319. Koomen, J.M.; Smalley, K.S. Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. Oncotarget, 2011, 2(4), 329-335.
320. Ley, R.; Ewings, K.E.; Hadfield, K.; Cook, S.J. Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ., 2005, 12(8), 1008-1014.
321. Zitzmann, K.; De Toni, E.; Von Ruden, J.; Brand, S.; Goke, B.; Laubender, R.P.; Auernhammer, C.J. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. Endocr. Relat. Cancer, 2011, 18(2), 277-285.
322. Meng, J.; Fang, B.; Liao, Y.; Chresta, C.M.; Smith, P.D.; Roth, J.A. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS One, 2010, 5(9), e13026.
323. Nishioka, C.; Ikezoe, T.; Yang, J.; Yokoyama, A. Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1. Apoptosis, 2010, 15(7), 795-804.
324. Bhalla, S.; Evens, A.M.; Dai, B.; Prachand, S.; Gordon, L.I.; Gartenhaus, R.B. The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. Blood, 2011, 118(4), 1052-1061.